查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2014681

胃癌治療市場：2026-2032年全球市場預測（依治療分類、治療階段、給藥途徑、劑型、治療方法及通路分類）

Gastric Cancer Drugs Market by Therapeutic Class, Treatment Line, Route Of Administration, Dosage Form, Therapy Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，胃癌治療市場價值將達到 43.1 億美元，到 2026 年將成長至 45.8 億美元，到 2032 年將達到 66.3 億美元，複合年成長率為 6.34%。

主要市場統計數據
基準年 2025 43.1億美元
預計年份：2026年 45.8億美元
預測年份 2032 66.3億美元
複合年成長率 (%) 6.34%

簡要概述影響胃癌治療的不斷發展的臨床和商業生態系統，以及相關人員的策略重點。

胃癌的治療仍是一個複雜的領域，涉及生物學、臨床實踐和醫療政策的交叉融合，共同影響著患者的預後。近年來，分子層面表徵的進步、多學科治療方法的廣泛應用以及免疫療法和標靶治療的引入，推動了臨床醫生在胃癌的診斷、分期和治療方法的快速發展。這些進展改變了治療路徑，也為製藥公司、保險公司和醫療服務提供者帶來了獨特的機會和挑戰，他們需要適應新的療效和安全性特徵以及不斷發展的治療標準。

精準醫療、免疫腫瘤學的進步以及不斷變化的法規和報銷獎勵如何從根本上重塑胃癌治療的模式。

胃癌治療領域正經歷變革性的轉變，涵蓋科學創新、監管方法和醫療服務模式等各個面向。在科學層面，精準腫瘤學正加速融入標準工作流程。分子分型和基於生物標記的患者篩選現已成為治療方案製定和臨床試驗設計的常規手段。這種向個人化醫療的轉變提升了伴隨診斷的重要性，並催生了對在明確定義的生物標記層級內驗證療效的臨床試驗的需求。同時，免疫腫瘤學正拓展至胃癌領域，引入了查核點抑制劑和聯合治療，旨在利用標靶治療與免疫微環境之間的協同作用。

評估近期關稅變化和貿易政策轉變對治療性原料和成品策略供應鏈、定價和准入的影響。

2025年，影響藥品、組件及相關生物製藥原料的關稅政策將使全球供應鏈和商業活動更加複雜。關稅調整可能會增加進口活性藥物成分、實驗室耗材和某些成品製劑的到岸成本，從而對製造地和籌資策略造成壓力。擁有全球分散供應鏈的製造商需要重新審視與供應商的契約，並考慮諸如近岸外包、雙重採購和增加庫存緩衝等方案，以減輕關稅價格波動的影響。

將治療領域、治療線、通路、給藥途徑、劑型和治療成分與其臨床和商業性意義聯繫起來的特定細分市場洞察。

將胃癌治療市場細分，有助於明確臨床價值和商業性機會的交會點，並突顯產品特性差異如何影響其應用和市場定位。根據治療分類，生物製藥（包括細胞激素和單株抗體）、化療藥物（包括Fluoropyrimidines、含鉑類藥物藥物和紫杉烷類）、免疫療法（包括癌症疫苗和查核點抑制劑）以及標靶治療（包括HER2抑制劑和VEGF抑制劑）各自擁有獨特的研發路徑和證據要求，並與診斷、聯合治療策略和安全性監測產生獨特的相互作用。生物製藥製劑亞類之間的差異在生產複雜性和監管要求方面特別顯著，而化療的既定作用構成了許多聯合治療的基礎，並影響著治療方案的選擇。

區域監管差異、支付方框架和醫療保健基礎設施決定了世界主要地區如何制定差異化的市場進入和商業化策略。

區域趨勢在塑造胃癌治療的發展重點、監管策略和商業化路徑方面發揮著至關重要的作用。在美洲，監管趨同和成熟的腫瘤學網路支持著那些展現出明確臨床獲益的創新療法的快速推廣應用，而支付方的嚴格審查和價值評估框架則要求提供強力的療效證據並確保價格與價值相符。此外，該地區的醫療保健系統越來越願意接受真實世界數據生成（REW）和基於價值的採購（VBP）試點項目，這些項目能夠在控制預算影響的同時，使患者儘早獲得治療。

深入了解各公司如何透過研究重點、夥伴關係結構、與診斷技術的整合以及生產策略，在胃癌治療領域實現差異化的競爭定位。

各公司針對胃癌治療的策略因研發重點、產品組合廣度及合作模式的不同而有所差異。一些機構將研發投入集中於發現下一代標靶治療和生物標記，優先考慮具有高臨床影響力的項目，即使其適應症有限。另一些機構則致力於聯合治療，將現有的化療藥物與免疫調節劑結合，旨在提高更廣泛患者群體的療效持久性。此外，越來越多的公司也開始重視診斷技術的合作開發和產品商品搭售，以最佳化病患篩選並加速健保報銷核准。

為開發人員和商業領袖提供切實可行的策略行動，以確保胃癌治療的臨床引入、供應鏈韌性和支付方合作。

致力於鞏固胃癌治療領域地位的產業領導者應優先考慮整合科學優勢、營運韌性和支付方合作的整合策略。首先，應儘早投資於生物標記發現和伴隨診斷夥伴關係，以最大限度地提高標靶治療和免疫調節項目的臨床和商業性回報。診斷是實現精準醫療適應症的關鍵要素，並有助於為醫保報銷談判提供強力的證據。其次，應重新設計供應鏈，透過採購多元化、探索區域生產方案和實施數位化追溯來提高柔軟性，從而提高採購預測的準確性，同時降低關稅和貿易風險。

我們透明的多來源調查方法，結合臨床證據審查、監管和支付方分析以及專家檢驗，得出可靠且可操作的見解。

本研究整合了公開的臨床文獻、監管決策、指南更新和專家訪談，建構了胃癌治療的多維度觀點。該方法結合了對同行評審的臨床研究和會議數據的定性主題分析，以及對腫瘤學家、藥物經濟學家和供應鏈專家的結構化訪談，以識別運營和准入方面的考慮因素。研究檢視了主要司法管轄區的監管路徑和政策趨勢，以了解核准趨勢和對上市後證據的預期，同時研究了與支付方相關的文獻，以確定常見的估值標準和合約慣例。

主要結論強調了綜合證據、生產靈活性和支付方合作是成功引入胃癌治療治療方法的決定因素。

胃癌治療正處於一個十字路口，科學機會與複雜的運作和政策現實交織在一起。標靶治療、免疫腫瘤學和藥物科學的創新有望改善特定患者群體的治療效果，但要實現廣泛且永續的治療，需要證據累積、價值鏈策略以及價值論證的精心協調。積極投資於診斷、敏捷生產和可操作證據累積的利害關係人，將更有能力將臨床創新轉化為永續的臨床和商業性影響。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療分類分類的胃癌治療市場

  • 生物製藥
    • 細胞激素
    • 單株抗體
  • 化療
    • Fluoropyrimidines
    • 含鉑類藥物
    • 紫杉烷類藥物
  • 免疫療法
    • 癌症疫苗
    • 查核點抑制劑
  • 分子標靶治療
    • HER2抑制劑
    • VEGF抑制劑

第9章：胃癌治療市場：依治療階段分類

  • 第 1 行
  • 第二行
  • 從第三行開始

第10章：胃癌治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第11章 胃癌治療市場：以劑型分類

  • 膠囊
  • 凍乾粉
  • 預填充式注射器
  • 藥片

第12章：胃癌治療市場：依治療方法

  • 聯合治療
  • 單藥治療

第13章：胃癌治療市場：依通路分類

  • 醫院藥房
  • 零售藥房

第14章 胃癌治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：胃癌治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 胃癌治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國胃癌治療市場

第18章：中國胃癌治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen MA Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Eli Lilly and Company
  • F. Hofmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • Mallinckrodt PLC
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi Group
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceuticals Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-437E9896A4F6

The Gastric Cancer Drugs Market was valued at USD 4.31 billion in 2025 and is projected to grow to USD 4.58 billion in 2026, with a CAGR of 6.34%, reaching USD 6.63 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.31 billion
Estimated Year [2026] USD 4.58 billion
Forecast Year [2032] USD 6.63 billion
CAGR (%) 6.34%

A concise orientation to the evolving clinical and commercial ecosystem shaping gastric cancer therapeutics and strategic priorities for stakeholders

Gastric cancer remains a complex therapeutic area where biology, clinical practice, and health system policy intersect to shape patient outcomes. Recent years have seen a rapid evolution in how clinicians diagnose, stage, and treat gastric malignancies, driven by improved molecular characterization, broader adoption of multimodal therapy, and the introduction of immune and targeted agents. These developments have altered treatment pathways and created distinct opportunities and challenges for pharmaceutical developers, payers, and providers as they adapt to new efficacy and safety profiles and shifting standards of care.

This summary synthesizes the most relevant trends influencing therapeutic development and commercialization. It highlights changes in clinical paradigms, commercial dynamics, and regulatory patterns that are redefining value capture in gastric oncology. By focusing on actionable insights rather than raw market estimates, the narrative emphasizes the nexus between clinical evidence, treatment access, and strategic positioning. The aim is to equip executives, clinical leaders, and investor stakeholders with a concise but comprehensive orientation to the landscape so they can prioritize investments, refine go-to-market approaches, and anticipate near-term inflection points that will affect program viability and patient access.

How precision medicine, immuno-oncology advances, and evolving regulatory and reimbursement incentives are fundamentally reshaping gastric cancer treatment paradigms

The therapeutic landscape for gastric cancer is experiencing transformative shifts that span scientific innovation, regulatory approaches, and care delivery models. On the scientific front, the integration of precision oncology into standard workflows has accelerated; molecular subtyping and biomarker-driven patient selection are now routinely informing therapeutic decisions and trial design. This movement toward individualized therapy has elevated the importance of companion diagnostics and created demand for trials that demonstrate benefit in well-defined biomarker strata. Concurrently, immuno-oncology has extended into gastric cancer with checkpoint inhibitors and combinatorial regimens that aim to leverage synergy between targeted agents and the immune microenvironment.

Regulatory frameworks are adapting to these scientific advances by streamlining pathways for accelerated approval based on surrogate endpoints in populations with high unmet need, while simultaneously stressing post-approval evidence generation to confirm clinical benefit. Payers and health systems are responding by developing outcome-based contracting mechanisms and by scrutinizing real-world evidence to guide coverage decisions. These dynamics are catalyzing collaborative models where manufacturers, providers, and diagnostic developers align on evidence generation and reimbursement strategies. Together, these shifts are reshaping clinical trial priorities, commercial models, and investment strategies across the value chain.

Assessing the strategic supply chain, pricing, and access implications resulting from recent tariff changes and trade policy shifts affecting therapeutic inputs and finished products

In 2025, tariff policies affecting pharmaceuticals, components, and related biologics inputs introduced a new layer of complexity across global supply chains and commercial operations. Tariff adjustments have the potential to increase landed costs for imported active pharmaceutical ingredients, laboratory consumables, and certain finished formulations, exerting pressure on manufacturing footprints and procurement strategies. Manufacturers with globally dispersed supply chains must reassess supplier contracts and consider options such as nearshoring, dual sourcing, and increased inventory buffering to mitigate exposure to tariff-driven price volatility.

The cumulative impact is felt across procurement, pricing, and market access. Hospitals and health systems that rely on international suppliers may face higher acquisition costs, which can translate into tighter formulary negotiations and more rigorous health technology assessments. Manufacturers are incentivized to optimize manufacturing locality and to invest in supply chain transparency to support cost-containment discussions with payers. In parallel, companies may accelerate conversations about value-based agreements that decouple price from volume and focus reimbursement on demonstrated clinical outcomes. These shifts also create opportunities for regional manufacturing partnerships and for suppliers that can demonstrate tariff-resilient sourcing and rapid quality assurance processes. Ultimately, tariff changes increase the strategic importance of supply chain agility and evidence that supports durable access in affected markets.

Segment specific insights that connect therapeutic class, line of therapy, distribution pathway, administration route, dosage formulation, and therapy composition to clinical and commercial implications

Segmenting the gastric cancer therapeutics landscape clarifies where clinical value and commercial opportunity intersect, and it highlights how different product characteristics influence adoption and positioning. Based on therapeutic class, Biologics including cytokines and monoclonal antibodies, Chemotherapy including fluoropyrimidines, platinum-based agents, and taxanes, Immunotherapy encompassing cancer vaccines and checkpoint inhibitors, and Targeted Therapy with Her2 inhibitors and Vegf inhibitors each have distinct development pathways and evidence requirements, and they interact with diagnostics, combination strategies, and safety monitoring in unique ways. The differentiation between biologic subclasses matters for manufacturing complexity and regulatory expectations, while the established roles of chemotherapy anchor many combination regimens and influence line-of-therapy decisions.

Based on treatment line, differences between first line, second line, and third line or later therapies govern trial design, comparator selection, and the magnitude of unmet need that a new therapy must address. First-line innovations typically require broader safety tolerability and demonstrable improvement in survival or quality of life, whereas later-line agents may gain approval based on smaller, biomarker-enriched populations with clinically meaningful responses. Based on distribution channel, the split between hospital pharmacies and retail pharmacies affects channel economics, patient access points, and the logistics of reimbursement and adherence support. Based on route of administration, the divergence among intravenous, oral, and subcutaneous modalities has implications for site-of-care, patient convenience, adherence, and cost structures, with oral and subcutaneous options often enabling outpatient management and potential shifts away from infusion center utilization.

Based on dosage form, considerations around capsules, lyophilized powder, pre-filled syringe, and tablets extend beyond patient preferences to stability, cold chain logistics, and compounding requirements, which in turn influence procurement and inventory policies. Finally, based on therapy type, the strategic choices between combination therapy and monotherapy drive clinical development complexity, regulatory interactions, and commercial narratives; combination regimens can deliver incremental efficacy but require careful safety management and co-development coordination. Taken together, these segmentation lenses provide a structured framework to prioritize development programs, design differentiated clinical trials, and craft market access strategies that align product attributes with clinical practice and payer expectations.

How regional regulatory diversity, payer frameworks, and healthcare infrastructure dictate differentiated market access and commercialization strategies across major global regions

Regional dynamics play a pivotal role in shaping development priorities, regulatory strategy, and commercialization approaches for gastric cancer therapies. In the Americas, regulatory convergence and established oncology networks support rapid adoption of innovations that demonstrate clear clinical benefit, yet payer scrutiny and value assessment frameworks require robust outcomes evidence and price-value alignment. Health systems in the region are also increasingly receptive to real-world evidence generation and value-based purchasing pilots that can enable earlier patient access while managing budget impact.

In Europe, Middle East & Africa, heterogeneity across regulatory environments and reimbursement pathways necessitates tailored market access strategies and flexible pricing models. While some jurisdictions exhibit strict health technology assessment protocols with cost-effectiveness thresholds, others prioritize access through managed entry agreements or conditional reimbursement linked to post-market evidence. Capacity constraints and variations in diagnostic availability in parts of the region underscore the need for deployment plans that include diagnostic enablement and capacity building to realize the full potential of targeted therapies. In Asia-Pacific, high incidence rates in certain countries, combined with rapidly modernizing clinical infrastructure, create strong demand for therapies that address region-specific molecular epidemiology. Regulatory authorities across Asia are increasingly harmonizing pathways and engaging in expedited review processes for priority medicines, while local manufacturing and licensing partnerships remain central to scaling access and managing commercial risk. Across all regions, alignment between evidence generation, pricing approaches, and delivery infrastructure is essential to convert clinical innovation into broader population impact.

Insights into how research focus, partnership structures, diagnostic integration, and manufacturing strategies differentiate company competitive positioning in gastric cancer therapeutics

Company strategies in gastric cancer therapeutics are diverging along research intensity, portfolio breadth, and partnership models. Some organizations concentrate R&D investment on next-generation targeted agents and biomarker discovery, prioritizing programs that enable narrow indication approvals but high clinical impact. Others pursue combination regimens that pair established chemotherapeutics with immuno-modulatory agents to enhance response durability in broader populations. A growing subset of companies is emphasizing diagnostic co-development and commercial bundling to support precise patient selection and to accelerate reimbursement acceptance.

Commercially, leading firms are experimenting with differentiated pricing approaches, evidence generation partnerships, and lifecycle management strategies that extend utility through new dosage forms or administration routes. Strategic alliances between biotechnology innovators and larger specialty pharmaceutical companies continue to be a dominant model for scaling manufacturing, regulatory submissions, and global commercialization. Additionally, companies with integrated manufacturing capabilities and regional production footprints are better positioned to navigate trade policy shifts and to respond rapidly to formulary decisions. Across the ecosystem, success increasingly depends on demonstrating meaningful patient benefit in real-world settings and on establishing collaborative arrangements with providers and payers to align incentives around value and access.

Practical and high impact strategic actions for developers and commercial leaders to secure clinical adoption, supply chain resilience, and payer alignment in gastric cancer care

Industry leaders seeking to strengthen their position in gastric cancer therapeutics should prioritize integrated strategies that align scientific differentiation with operational resilience and payer engagement. First, invest early in biomarker discovery and companion diagnostic partnerships to maximize the clinical and commercial returns of targeted and immuno-modulatory programs. Diagnostics are critical enablers of precision labeling and help build compelling dossiers for reimbursement discussions. Second, redesign supply chains for greater flexibility by diversifying sourcing, exploring regional manufacturing options, and implementing digital traceability to mitigate tariff and trade risks while improving procurement predictability.

Third, develop evidence generation plans that combine randomized trials with pragmatic real-world studies to address payer concerns about generalizability and long-term outcomes. Purposeful post-approval data collection can unlock managed entry agreements and outcome-based contracts. Fourth, evaluate administration route and dosage form innovation not only through a clinical lens but also as a commercial lever to shift site-of-care, improve adherence, and reduce total cost of care. Fifth, pursue value-focused pricing strategies and commercial models that emphasize demonstrable improvements in survival, quality of life, or healthcare utilization, enabling constructive dialogues with payers and health systems. By implementing these actions in a coordinated manner, organizations can reduce execution risk and accelerate the translation of clinical advances into sustained patient access.

A transparent multi-source methodology combining clinical evidence review, regulatory and payer analysis, and expert validation to derive robust actionable insights

This research synthesized publicly available clinical literature, regulatory decisions, guideline updates, and expert interviews to build a multi-dimensional perspective on gastric cancer therapeutics. The approach combined qualitative thematic analysis of peer-reviewed clinical studies and conference data with structured interviews of oncologists, pharmacoeconomists, and supply chain specialists to capture operational and access considerations. Regulatory pathways and policy developments were reviewed across major jurisdictions to understand approval trends and post-market evidence expectations, and payer literature was examined to identify common value assessment criteria and contracting practices.

Where appropriate, secondary sources were cross-checked against primary documents such as clinical trial protocols, regulatory agency summaries, and professional society guideline statements to ensure factual accuracy. Expert validation workshops were used to refine interpretations and to prioritize strategic implications. The methodology emphasized triangulation across evidence streams and transparent documentation of assumptions to provide stakeholders with a credible and actionable synthesis rather than speculative projections.

A synthesis of key conclusions emphasizing integrated evidence, manufacturing agility, and payer collaboration as the determinants of successful therapeutic adoption in gastric oncology

Gastric cancer therapeutics are at an inflection point where scientific opportunity meets complex operational and policy realities. Innovations in targeted therapies, immuno-oncology, and formulation science promise improved outcomes for defined patient populations, yet achieving broad and sustainable access will require deliberate alignment of evidence generation, supply chain strategy, and value demonstration. Stakeholders that proactively invest in diagnostics, agile manufacturing, and pragmatic evidence generation will be better positioned to convert clinical innovation into durable clinical and commercial impact.

Looking ahead, the most successful programs will be those that integrate clinical differentiation with operational readiness and that engage payers and providers early to co-design access pathways. By focusing on these integrated priorities, organizations can reduce uncertainty, accelerate adoption, and ultimately improve therapeutic options for patients living with gastric cancer.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastric Cancer Drugs Market, by Therapeutic Class

  • 8.1. Biologics
    • 8.1.1. Cytokines
    • 8.1.2. Monoclonal Antibodies
  • 8.2. Chemotherapy
    • 8.2.1. Fluoropyrimidines
    • 8.2.2. Platinum-Based Agents
    • 8.2.3. Taxanes
  • 8.3. Immunotherapy
    • 8.3.1. Cancer Vaccines
    • 8.3.2. Checkpoint Inhibitors
  • 8.4. Targeted Therapy
    • 8.4.1. Her2 Inhibitors
    • 8.4.2. Vegf Inhibitors

9. Gastric Cancer Drugs Market, by Treatment Line

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third Line Or Later

10. Gastric Cancer Drugs Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Gastric Cancer Drugs Market, by Dosage Form

  • 11.1. Capsules
  • 11.2. Lyophilized Powder
  • 11.3. Pre-Filled Syringe
  • 11.4. Tablets

12. Gastric Cancer Drugs Market, by Therapy Type

  • 12.1. Combination Therapy
  • 12.2. Monotherapy

13. Gastric Cancer Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Retail Pharmacies

14. Gastric Cancer Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Gastric Cancer Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Gastric Cancer Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Gastric Cancer Drugs Market

18. China Gastric Cancer Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. Astellas Pharma Inc.
  • 19.8. AstraZeneca PLC
  • 19.9. Bayer AG
  • 19.10. Biogen MA Inc.
  • 19.11. Boehringer Ingelheim GmbH
  • 19.12. Bristol-Myers Squibb Company
  • 19.13. Cipla Limited
  • 19.14. Eli Lilly and Company
  • 19.15. F. Hofmann-La Roche Ltd.
  • 19.16. Gilead Sciences, Inc.
  • 19.17. GlaxoSmithKline PLC
  • 19.18. Incyte Corporation
  • 19.19. Ipsen Pharma
  • 19.20. Johnson & Johnson Services, Inc.
  • 19.21. Mallinckrodt PLC
  • 19.22. Merck KGaA
  • 19.23. Novartis AG
  • 19.24. Pfizer, Inc.
  • 19.25. Regeneron Pharmaceuticals, Inc.
  • 19.26. Sanofi Group
  • 19.27. Sumitomo Pharma Co., Ltd.
  • 19.28. Sun Pharmaceuticals Limited
  • 19.29. Takeda Pharmaceutical Company Limited
  • 19.30. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTRIC CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GASTRIC CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FLUOROPYRIMIDINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PLATINUM-BASED AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PLATINUM-BASED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PLATINUM-BASED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TAXANES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TAXANES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HER2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HER2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THIRD LINE OR LATER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THIRD LINE OR LATER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THIRD LINE OR LATER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 201. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 203. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 234. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 236. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 240. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 245. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 247. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)